ArticleBMC neurology2025
Disease characteristics and treatment status of genetically confirmed spinal muscular atrophy patients: a cross-sectional survey in China.
Article in BMC neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThis cross-sectional study aimed to investigate the disease status, motor function, and medication treatment choices of genetically confirmed SMA patients.
methodsA single-center, cross-sectional survey was conducted using web-based questionnaires and telephone interviews. Data were collected from genetically diagnosed SMA patients, including general information, SMA complications, motor function and medication treatment regimens.
resultsAmong the 106 patients finally included in analysis, the median age was 18.5 years (IQR, 14.00-25.75), with SMA types distributed as 10.4% type 1, 40.6% type 2, and 49.0% type 3. Despite the high prevalence of spinal deformities (84.0%) and joint deformities (82.1%), motor function was Generally well-maintained, with 51.9% of patients able to sit independently. The willingness of parents of patients who did not receive DMT treatment to have another child was lower than the willingness of parents of patients who had received DMT treatment (OR: 0.195; 95% CI: 0.068-0.562; P = 0.002). Notably, 66.0% had used nusinersen and 24.5% had used risdiplam. When selecting medications, the primary considerations among all patients included drug efficacy, safety, and cost. However, 48.8% of the patients who received treatment reported treatment dissatisfaction due to perceived poor efficacy and high costs. The efficacy outcomes most commonly recognized by patients included delaying disease progression, improving symptoms, and enhancing quality of Life. Additionally, 70.8% of SMA patients preferred solely oral medication therapy.
conclusionsPatients with different subtypes of SMA are currently experiencing various complications while maintaining good motor function. In the future, there is a significant need for enhanced patient education about DMTs knowledge.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.